Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Breast Cancer
Interventions
DRUG

Paclitaxel 80 mg/m2

Paclitaxel 80 mg/m2 days 1, 8 and 15

DRUG

Nab-paclitaxel 100 mg/m2 days 1, 8 and 15

Nab-paclitaxel 100 mg/m2 days 1, 8 and 15

DRUG

Nab-paclitaxel 150 mg/m2 days 1, 8 and 15

Nab-paclitaxel 150 mg/m2 days 1, 8 and 15

DRUG

Nab-paclitaxel 150 mg/m2 days 1 and 15

Nab-paclitaxel 150 mg/m2 days 1 and 15

Trial Locations (10)

28031

Hospital Universitario Infanta Leonor, Madrid

28034

Hospital Ramón Y Cajal, Madrid

28040

Hospital Clínico San Carlos, Madrid

28222

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda

28500

Hospital Universitario Del Sureste, Arganda

28905

Hospital Universitario de Getafe, Getafe

28911

Hospital Universitario Severo Ochoa, Leganés

28942

Hospital Universitario de Fuenlabrada, Fuenlabrada

28981

Hospital Universitario Infanta Cristina, Parla

Unknown

Hospital 12 de Octubre, Madrid

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Fundacion Oncosur

NETWORK

NCT01763710 - Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter